J7608 HCPCS Level II code: Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram
J7608 is the HCPCS code for “Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7608Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram
Short description: Acetylcysteine non-comp unit
HCPCS · United States
Notes for J7608
As CMS prints them, with any note J7608 takes from the headings above it.
Note
- CMS processing note 0135: MEDICARE BENEFIT POLICY MANUAL, PUB 100.2, CHAPTER 15, SECTION 110.3 (100.02,15,110.3).
Medicare details
The indicators CMS publishes with J7608 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Drugs Administered through DME
- Added
- Jan 1, 2000
Where J7608 sits
- 1J codesDrugs administered other than orally
- 2Active code J7608Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7608 mean?
J7608 is the HCPCS code for “Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7608?
CMS lists J7608’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7608
All J codesJ7599Immunosuppressive drug, not otherwise classifiedJ7601Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mgJ7604Acetylcysteine, inhalation solution, compounded product, administered through dme, unit dose form, per gramJ7605Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 microgramsJ7606Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 microgramsJ7607Levalbuterol, inhalation solution, compounded product, administered through dme, concentrated form, 0.5 mgJ7609Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mgJ7610Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mgJ7611Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mgJ7612Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mgJ7613Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mgJ7614Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg